Gustavo Monnerat, Deputy Editor at The Lancet, shared a post on LinkedIn:
“Nature Medicine recently published clinical trials most likely to shape medical practice in the coming years.
Among all of them, these are the ones I personally found most interesting:
A next-generation tuberculosis vaccine (M72/AS01E):
The current BCG vaccine works reasonably well in young children, but its protection fades in adolescents and adults. This large phase 3 trial, enrolling 20,000 participants across Africa and Asia, aims to prevent progression to active pulmonary TB.
Targeting inflammation in heart disease (IL-6 inhibition with ziltivekimab):
This trial moves cardiovascular prevention beyond cholesterol lowering. By targeting residual inflammatory risk, it reinforces a crucial idea of an inflammation cause.
Two approaches stood out:
- mRNA CAR-T therapies that temporarily reprogram immune cells without permanent DNA editing
- Prime editing of autologous stem cells, correcting genetic defects using the patient’s own cells, with early signals suggesting functional cures in rare diseases.”
Read the full article: Eleven clinical trials that will shape medicine in 2026.